--- title: Which Diseases Can HSCT Treat, and Who May Need a Transplant? url: "https://www.yyhmedical.com/en/faq/hematopoietic-stem-cell-transplant-basic-knowledge/hematopoietic-stem-cell-transplantation-diseases-and-indications" type: FAQPage inLanguage: en-US lastReviewed: 2023-12-01 datePublished: 2023-12-01 --- # Which Diseases Can HSCT Treat, and Who May Need a Transplant? > Find out which blood cancers, bone marrow failure disorders, inherited conditions, and immune deficiencies may be treated with HSCT. ## Which Diseases Can HSCT Treat, and Who May Need a Transplant? Overview: Hematopoietic stem cell transplantation (HSCT) uses healthy blood-forming stem cells to rebuild blood production and immune function. It may be used for selected blood cancers, bone marrow failure disorders, inherited conditions, and immune deficiencies. Whether a person needs HSCT depends on the disease, risk group, genetic test results, response to treatment, and overall health. HSCT is not the right option for everyone. **Which diseases may be treated with HSCT?** HSCT is not used only for leukemia. It is an important treatment for several types of blood and immune disorders, including blood cancers, bone marrow failure, selected inherited diseases, and some immune system disorders. The reason for transplant and the treatment goal may differ from one disease to another. **Which patients with blood cancer may need HSCT?** Acute leukemia: HSCT may be considered for some patients with high-risk acute leukemia, relapsed leukemia, or disease that remains at high risk of returning after treatment. The goals may include reducing remaining abnormal cells, rebuilding healthy blood production, and using donor immune cells to fight leukemia. Not every patient with acute leukemia needs a transplant; some may achieve long-term remission with chemotherapy, targeted therapy, or immunotherapy. Myelodysplastic syndromes (MDS): MDS is a group of disorders caused by abnormal blood-forming stem cells. Some high-risk cases may progress to acute myeloid leukemia. For suitable patients, allogeneic HSCT is one of the treatments that may offer a chance of cure. Lymphoma: Autologous HSCT may be used for some patients with relapsed or treatment-resistant lymphoma, or as consolidation when the disease has responded to treatment but the risk of relapse remains high. The decision depends on the type and stage of lymphoma, previous treatment, treatment response, and overall health. Multiple myeloma: For eligible patients, autologous HSCT may be an important part of treatment. The team considers age, general health, organ function, disease control, and response to earlier treatment. **Which non-cancerous conditions may be treated with HSCT?** Aplastic anemia: Severe aplastic anemia occurs when the bone marrow cannot make enough red cells, white cells, and platelets. Allogeneic HSCT may be an important option for some younger, eligible patients who have a suitable donor. Inherited blood disorders: Some inherited conditions are caused by an abnormal blood-forming system. HSCT may correct the underlying problem in selected patients, including some people with thalassemia or inherited metabolic disorders. Immune deficiencies: Some congenital immune disorders prevent the immune system from working normally. HSCT may help rebuild immune function in selected patients. **Is HSCT suitable for every patient?** No. The transplant team assesses the disease type and risk, response to treatment, and the patient’s overall health. Disease type and risk matter because some lower-risk conditions may respond well to medicines, while high-risk disease may require earlier consideration of transplant. Treatment response also affects timing. The team may review whether leukemia is in complete remission, whether measurable residual disease (MRD) remains, and whether the disease burden is still high. Before transplant, heart, lung, liver, and kidney function are checked, along with infection status and general fitness, because conditioning and the early recovery period can place significant stress on the body. **Why do patients with the same disease receive different plans?** Blood diseases are highly variable. Even patients with the same diagnosis may have different genetic changes, risk levels, ages, health conditions, and responses to treatment. Modern care therefore uses risk-based and personalized treatment. The transplant team reviews the full set of test results to decide whether HSCT is likely to provide more benefit than risk. **What preparation is needed before HSCT?** Disease assessment may include bone marrow examination, immunophenotyping, chromosome tests, gene tests, and MRD testing. For allogeneic HSCT, donor assessment includes HLA matching, a health check for the donor, and planning the transplant approach. The patient also has assessments of heart, lung, liver, and kidney function, along with infection screening. These steps help reduce risk and improve safety. **Summary** HSCT is not a fixed treatment for one disease. It is an important option for selected blood cancers and related disorders. Today, transplant decisions are increasingly based on precise diagnosis, risk assessment, and the individual needs of each patient. ## Related questions ### Q1: Does every person with leukemia need HSCT? No. The decision depends on the type and risk of leukemia, genetic findings, and response to treatment. Some patients may do well with chemotherapy, targeted therapy, or immunotherapy, while others with high-risk or relapsed disease may need a transplant. ### Q2: Is HSCT always the final treatment option? No. For some high-risk patients, transplant may be planned while the disease is well controlled rather than waiting until all other options have failed. ### Q3: Is HSCT needed after CAR T-cell therapy? Some patients may need it. The team considers the response to CAR T-cell therapy, the risk of relapse, and the features of the disease before deciding whether a transplant should follow. ### Q4: Can I have a transplant if there is no fully matched sibling donor? Possibly. Donor options may include a haploidentical family member, an unrelated donor, or cord blood. The transplant team will assess which source is most suitable. ## Content attribution (YMYL) - Author: - Medically reviewed by: - Last reviewed:2023-12-01 - First published:2023-12-01 > --- Original (HTML):https://www.yyhmedical.com/en/faq/hematopoietic-stem-cell-transplant-basic-knowledge/hematopoietic-stem-cell-transplantation-diseases-and-indications This is a clean Markdown mirror for large language models; the original page is authoritative.